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Polymeric Adjuvants for Vaccine Delivery
Abstract
This research has further investigated the use of pentablock copolymers and polyanhydride
nanoparticles in combination to form a hydrogel matrix giving controlled and sustained release
of model protein ovalbumin (OVA). To investigate the effect of changes in the hydrogel matrix
on the release of OVA, the composition of hydrogel components, form of OVA, and molecular
weight of pentablock copolymer were varied. The weight percent of polyvinyl alcohol (PVA)
was tested for 20% and 30%. Molecular weight of the pentablock copolymer was also varied
giving a low molecular weight (≈18 kDa) or high molecular weight (≈ 25 kDa) copolymer.
Lastly, OVA protein was incorporated into hydrogels either in a free form (1 mg/mL solution in
phosphate buffered saline (PBS)), encapsulated in polyanhydride nanoparticles (CPTEG:CPH-
50:50), or a combination of the two. For all trials, the total OVA amount was maintained at 60
μg per 1 mL volume of hydrogel, and release profiles were observed for 4 days. Overall,
release profiles of OVA from hydrogels confirmed the gradual and controlled release of protein
with time. They also showed that the amount of protein released from 20% PVA hydrogels was
greater than the protein released from 30% hydrogels due to structural differences of the
matrices. Lastly, the encapsulated OVA versus free OVA clearly influenced total protein
amount released and varied with % PVA and molecular weight of copolymer.
Materials and Methods
Synthesis of Pentablock Copolymers
The polymer was synthesized with Pluronic F127 microinitiator of poly(propylene-oxide)
and poly(ethylene-oxide), diethylaminoethyl methacrylate (DEAEM) monomer, and N-
propyl-pyridynyl methanimine (NPPM) ligand. The polymer solution was placed in an oil
bath for 24 and 36 hr to achieve 18 kDa and 25 kDa respectively.
Conclusions
• Pentablock copolymer and polyanhydride nanoparticle hybrid hydro-
gels gave sustained and controlled release of OVA over 4-day duration
• Clear influence on release of OVA from pentablock copolymer
molecular weight and form of OVA
• OVA release is affected by PVA weight percent in hydrogel; 20% PVA
hydrogels have higher release rate than 30% PVA hydrogels
Results
Future Considerations
• Further testing of pentablock copolymer molecular weight and weight
percentages of PVA
• Calculate diffusion coefficients of OVA protein out of hydrogel
• Choose specific antigens to test release from hydrogels
• Conduct in vivo tests with optimized hydrogel parameters
Motivations
• Effective and controlled release of active components is crucial in the
efficacy of vaccine and drug delivery applications
• Temperature and pH responsive amphiphilic pentablock copolymers and
surface eroding polyanhydride nanoparticles show promise as vaccine
adjuvants
Creation of Hydrogels
Hydrogels were created using either 20% or 30% weight PVA, 59 mg of pluronic F127 initiator, 41 mg of
pentablock copolymer, and PBS. For each hydrogel, OVA was loaded in either a A) free form, B)
encapsulated, or C) 50:50 free and encapsulated OVA. Each hydrogel composition had 3 replicates (333
μL each) for release trials.
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Figure 4: Different forms of OVA loaded into hydrogels. A) free OVA, B) encapsulated OVA in
CPTEG:CPH nanoparticles, C) 50:50 ratio of free OVA and encapsulated OVA
Figure 6: Release data for high molecular weight copolymer and 30% PVA (left) or 20% PVA (right)
Figure 7: Comparing OVA release between 20% and 30% PVA hydrogels
Figure 8: Comparing OVA release between low and high molecular weight copolymers in 30% PVA
Figure 1:Molecular structure of pentablock copolymer
Figure 3:Molecular structure of polyanhydride nanoparticles
Encapsulation of Ovalbumin (OVA) in Polyanhydride Nanoparticles
The OVA particles were encapsulated in a 50:50 ratio of poly[1,6-bis(p-carboxyphenoxy)hexane] (CPH)
and poly[1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane] (CPTEG) nanoparticles using spray drying.
Figure 2: NMR spectroscopies for low (left) and high molecular weight (right) pentablock copolymer
Figure 5: Release data for low molecular weight copolymer and 30% PVA (left) or 20% PVA (right)
